FY2025 Earnings Estimate for EW Issued By Leerink Partnrs

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Equities researchers at Leerink Partnrs lifted their FY2025 EPS estimates for shares of Edwards Lifesciences in a research note issued on Thursday, April 24th. Leerink Partnrs analyst M. Kratky now forecasts that the medical research company will earn $2.48 per share for the year, up from their prior forecast of $2.42. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences' FY2027 earnings at $3.22 EPS.

A number of other analysts have also commented on the stock. Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. Evercore ISI reduced their target price on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Royal Bank of Canada reiterated an "outperform" rating and set a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Truist Financial reduced their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Finally, Robert W. Baird lifted their target price on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of "Hold" and a consensus price target of $79.25.

Edwards Lifesciences Trading Up 6.7 %

Shares of NYSE EW opened at $75.15 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a market cap of $44.18 billion, a price-to-earnings ratio of 10.78, a P/E/G ratio of 4.82 and a beta of 1.15. The business has a fifty day simple moving average of $70.93 and a 200-day simple moving average of $71.02.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. During the same period in the prior year, the company earned $0.66 EPS.

Hedge Funds Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $3,173,000. World Investment Advisors LLC boosted its stake in shares of Edwards Lifesciences by 1,660.7% in the 3rd quarter. World Investment Advisors LLC now owns 72,277 shares of the medical research company's stock valued at $4,770,000 after purchasing an additional 68,172 shares in the last quarter. Wilmington Savings Fund Society FSB grew its holdings in shares of Edwards Lifesciences by 147.0% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 9,106 shares of the medical research company's stock worth $601,000 after purchasing an additional 5,420 shares during the last quarter. Destination Wealth Management increased its position in shares of Edwards Lifesciences by 2.8% during the 3rd quarter. Destination Wealth Management now owns 7,012 shares of the medical research company's stock worth $463,000 after purchasing an additional 193 shares in the last quarter. Finally, Tidal Investments LLC lifted its holdings in Edwards Lifesciences by 0.7% during the 3rd quarter. Tidal Investments LLC now owns 39,532 shares of the medical research company's stock valued at $2,609,000 after purchasing an additional 275 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 400 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the sale, the vice president now owns 22,588 shares in the company, valued at $1,569,414.24. This represents a 1.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,555,402. This represents a 12.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,853 shares of company stock worth $5,163,062 over the last 90 days. Insiders own 0.34% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.